| Dr Jose Augusto Villamil, MD | |
|
865 Stone St, Rahway, NJ 07065-2742 | |
| (888) 724-7123 | |
| Not Available |
| Full Name | Dr Jose Augusto Villamil |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 19 Years |
| Location | 865 Stone St, Rahway, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619208543 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 266606 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Robert Wood Johnson University Hospital At Rahway | Rahway, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
| Maimonides Faculty Practice Plan | 7012808348 | 195 |
| Medical Health 360 Pllc | 7315351046 | 6 |
| Rwjbh Emergency Medicine Associates, Llc | 0941612840 | 613 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
| Entity Name | Maimonides Medical Center Maimonides Primary Care Fpp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013968593 PECOS PAC ID: 5991696916 Enrollment ID: O20040322000161 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
| Entity Name | Maimonides Faculty Practice Plan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053344846 PECOS PAC ID: 7012808348 Enrollment ID: O20040324000597 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
| Entity Name | Medical Health 360 Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497374359 PECOS PAC ID: 7315351046 Enrollment ID: O20210120002985 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jose Augusto Villamil, MD 379 Campus Dr Fl 4, Somerset, NJ 08873-1161 Ph: (732) 937-8939 | Dr Jose Augusto Villamil, MD 865 Stone St, Rahway, NJ 07065-2742 Ph: (888) 724-7123 |
News Archive
The Beryl Institute released a report highlighting results from its recent patient experience benchmarking study conducted in collaboration with Catalyst Healthcare Research, an independent marketing research firm.
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
› Verified 5 days ago
Dr. Arthur Francis Santiago, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 307 Grove St, Rahway, NJ 07065 Phone: 732-382-3390 | |
Dr. Richard Koku Amegadzie, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1044 E Hazelwood Ave, Rahway, NJ 07065 Phone: 732-381-3636 Fax: 732-381-5977 | |
Monica Ann Arnold, D.O. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1600 St. Georges Avenue Parkside Plaza, Suite 111, Rahway, NJ 07065 Phone: 732-388-2422 Fax: 732-388-1706 | |
Muhammad Afzal Khan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 865 Stone St, Rahway, NJ 07065 Phone: 732-937-8939 Fax: 845-483-6376 | |
Dr. Frances Dae Il Yim, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 913 W Inman Ave, Rahway, NJ 07065 Phone: 732-388-7999 Fax: 732-388-7992 | |
Ms. Silviya Perookunnel, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 865 Stone St, Rahway, NJ 07065 Phone: 732-937-8939 | |
Charlene Louise Vojnyk, Internal Medicine Medicare: Medicare Enrolled Practice Location: 546 Saint Georges Ave, Rahway, NJ 07065 Phone: 732-381-3642 Fax: 732-396-4463 |